Head to Head Survey: Eloxx Pharmaceuticals (ELOX) and PRA Health Sciences (PRAH)
PRA Health Sciences (NASDAQ:PRAH) and Eloxx Pharmaceuticals (OTCMKTS:ELOX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.
Risk and Volatility
PRA Health Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
This table compares PRA Health Sciences and Eloxx Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|PRA Health Sciences||$2.26 billion||2.82||$86.92 million||$3.20||30.92|
|Eloxx Pharmaceuticals||$80,000.00||5,763.80||-$21.21 million||N/A||N/A|
PRA Health Sciences has higher revenue and earnings than Eloxx Pharmaceuticals.
This table compares PRA Health Sciences and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PRA Health Sciences||4.25%||24.52%||7.00%|
Institutional & Insider Ownership
98.8% of PRA Health Sciences shares are held by institutional investors. 0.9% of PRA Health Sciences shares are held by company insiders. Comparatively, 44.0% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of recent ratings and target prices for PRA Health Sciences and Eloxx Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PRA Health Sciences||0||2||7||0||2.78|
PRA Health Sciences presently has a consensus price target of $111.11, indicating a potential upside of 12.29%. Eloxx Pharmaceuticals has a consensus price target of $25.25, indicating a potential upside of 90.89%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than PRA Health Sciences.
PRA Health Sciences beats Eloxx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About PRA Health Sciences
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.